Chung-wei Su

No.259, Wenhua 1st Rd, Taoyuan City 333
Taoyuan City, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma.

GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma.

Journal: Journal of Cancer

Published: February 24, 2026

Jaundice marks immunoglobulin G4-related cholangitis in type 1 autoimmune pancreatitis patients.

Jaundice marks immunoglobulin G4-related cholangitis in type 1 autoimmune pancreatitis patients.

Journal: Therapeutic advances in gastroenterology

Published: January 22, 2026

Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20-Year Population-Based Study.

Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20-Year Population-Based Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 13, 2025

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 30, 2025

Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab.

Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab.

Journal: Cancers

Published: August 26, 2025

Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.

Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.

Journal: Cancer immunology, immunotherapy : CII

Published: June 11, 2025

Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma.

Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma.

Journal: Liver cancer

Published: April 09, 2025

TKI plus ICI versus ICI alone in high tumor burden hepatocellular carcinoma: a retrospective cohort study.

TKI plus ICI versus ICI alone in high tumor burden hepatocellular carcinoma: a retrospective cohort study.

Journal: Journal of cancer research and clinical oncology

Published: February 15, 2025

Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients.

Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients.

Journal: Journal of hepatocellular carcinoma

Published: November 16, 2024

Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC.

Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC.

Journal: Hepatology (Baltimore, Md.)

Published: October 13, 2024

Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis.

Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis.

Journal: Cancers

Published: September 17, 2024

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Journal: Viruses

Published: August 22, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026